ARCA biopharma (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March 31, 2018.

As quoted in the press release:

“The first quarter of this year saw an important milestone for the Gencaro development program with the reporting of top-line Phase 2B results for the GENETIC-AF clinical trial evaluating Gencaro as potentially the first genetically-targeted treatment for atrial fibrillation,” commented Dr. Michael Bristow, ARCA’s President and Chief Executive Officer.  “Our End-of-Phase 2 meeting with the U.S. FDA is scheduled for the last week of June when we will review the data and potential future development plans for Gencaro.”

Click here to read the full press release.